Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Sera Prognostics, Inc. is a women’s health diagnostics company focused on improving maternal and neonatal outcomes by predicting and preventing complications of pregnancy. The company operates in the molecular diagnostics and precision medicine industries, applying proteomics and data science to blood-based testing. Its core commercial and clinical focus is on identifying pregnant women at elevated risk for adverse outcomes, particularly spontaneous preterm birth, an area with significant unmet medical need and high healthcare cost impact.
The company’s primary product is the PreTRM® Test, a laboratory-developed blood test designed to assess the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. Revenue to date has been driven primarily by testing services, research collaborations, and grant-supported clinical programs rather than broad commercial adoption. Sera Prognostics was founded in 2008 and has evolved from a research-focused enterprise into a publicly traded diagnostics company, completing its initial public offering in 2021 and continuing to pursue clinical validation, payer coverage, and guideline inclusion.
Business Operations
Sera Prognostics operates as a single-segment diagnostics business centered on pregnancy biomarker discovery, validation, and testing services. The company generates revenue through clinical testing, sponsored research agreements, and grant-funded programs supporting large-scale clinical studies. Its operations integrate proprietary proteomic biomarkers, algorithms, and laboratory processes to deliver predictive risk scores used by healthcare providers and researchers.
Operations are primarily based in the United States, with laboratory and administrative functions supported domestically. The company controls its proprietary biomarker intellectual property, data analytics platforms, and laboratory workflows. Sera Prognostics collaborates with academic institutions, healthcare systems, and public health organizations, including participation in large federally supported studies. Public disclosures indicate no material operating subsidiaries or joint ventures; data on additional commercial partnerships beyond research collaborations is inconclusive based on available public sources.
Strategic Position & Investments
Strategically, Sera Prognostics is focused on expanding clinical evidence, securing reimbursement coverage, and driving adoption of predictive pregnancy testing within standard obstetric care. Key growth initiatives include large prospective studies, health economic outcomes research, and engagement with payers and public health stakeholders to demonstrate cost savings and improved outcomes associated with early risk identification.
The company has not announced major acquisitions and instead invests primarily in internal research and development and externally funded clinical programs. Notable initiatives include participation in federally supported and foundation-backed studies aimed at validating the clinical utility of the PreTRM® Test across diverse populations. Sera Prognostics’ technology platform positions it at the intersection of proteomics, artificial intelligence-driven risk modeling, and maternal-fetal medicine, with potential applicability to additional pregnancy-related conditions over time.
Geographic Footprint
Sera Prognostics is headquartered in Salt Lake City, Utah, which serves as its primary operational and administrative center. The company’s commercial, laboratory, and research activities are largely concentrated in the United States, reflecting its current regulatory approvals, reimbursement focus, and clinical study footprint.
While the company does not maintain a broad physical presence outside the U.S., its research collaborations and published clinical studies have involved international investigators and datasets. International commercialization or direct operational expansion outside North America has not been disclosed as a near-term priority, and available public sources indicate limited direct international revenue contribution at this stage.
Leadership & Governance
Sera Prognostics was founded by Christy Minnis, PhD, who established the company’s scientific foundation around pregnancy proteomics and continues to play a key role in shaping its research-driven strategy. The leadership team emphasizes evidence-based medicine, clinical validation, and long-term integration into standard obstetric care pathways, with governance aligned toward scientific rigor and regulatory compliance as a publicly traded company.
Key executives include:
- Zhenya Lindgardt, PhD – Chief Executive Officer
- Christy Minnis, PhD – Founder and Chief Scientific Officer
Public filings confirm a board-led governance structure typical of U.S.-listed life sciences companies. Detailed information on additional executive officers beyond those listed above is inconsistent across public disclosures; data inconclusive based on available public sources.